Kadmon competitorsClear all

Kadmon's top competitors include Biogen, Athersys, Reata Pharmaceuticals and Otonomy.
Kadmon
Kadmon
Kadmon Corporation is a biopharmaceutical company offering products and services for the treatment and management of hepatitis C.
Biogen
Biogen
Biogen is a biopharmaceutical company that discovers, develops and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases.
Athersys
Athersys
Athersys, a biopharmaceutical company, discovers and develops therapeutic products for the treatment of several disease indications.
Reata Pharmaceuticals
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company focused on translating innovative science into breakthrough medicines for intractable diseases.
Otonomy
Otonomy
Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.
Founding Date
Founding Date
2010
Founding Date
1978
Founding Date
1995
Founding Date
2002
Founding Date
2008
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
New York, US HQ
Locations
Cambridge, US HQ
Vicente López, AR
North Ryde, AU
Wien, AT
Machelen, BE
Mississauga, CA
see more
Locations
Cleveland, US HQ
Canton, US
Locations
Irving, US HQ
Locations
San Diego, US HQ
Employees
Employees
11615% increase
Employees
7,8007% increase
Employees
7514% increase
Employees
12332% increase
Employees
498% decrease
Valuation ($)
Valuation ($)
252.5 m
Valuation ($)
44.3 b
Valuation ($)
241.1 m
Valuation ($)
N/A
Valuation ($)
73.6 m
Twitter followers
Twitter followers
N/A
Twitter followers
26.4 k
Twitter followers
1.2 k
Twitter followers
672
Twitter followers
233
Number of tweets (last 30 days)
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
48
Number of tweets (last 30 days)
4
Number of tweets (last 30 days)
13
Number of tweets (last 30 days)
N/A
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
24.9
Average likes per tweet (last 30 days)
21.3
Average likes per tweet (last 30 days)
2.1
Average likes per tweet (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
84.62%
Percentage of tweets with engagement (last 30 days)
N/A
Alexa Website Rank
Alexa Website Rank
1046585
Alexa Website Rank
83540
Alexa Website Rank
609659
Alexa Website Rank
787661
Alexa Website Rank
691980

Financial

Revenue (est.)
Revenue (est.)
$1.4m (FY, 2018)
Revenue (est.)
$11.4b (FY, 2016)
Revenue (est.)
$24.3m (FY, 2018)
Revenue (est.)
N/A
Revenue (est.)
$745k (FY, 2018)
Cost of goods
Cost of goods
$412k (FY, 2018)
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
$946k (FY, 2018)
Gross profit
Gross profit
$984k (FY, 2018)
Gross profit
N/A
Gross profit
N/A
Gross profit
N/A
Gross profit
($201k) (FY, 2018)
Net income
Net income
($54.3m) (FY, 2018)
Net income
$3.7b (FY, 2016)
Net income
N/A
Net income
($80.5m) (FY, 2018)
Net income
($50.4m) (FY, 2018)

Operating

Patents Issued
Patents Issued
N/A
Patents Issued
N/A
Patents Issued
200 (FY, 2016)
Patents Issued
240 (FY, 2016)
Patents Issued
88 (FY, 2016)
Patents Pending
Patents Pending
N/A
Patents Pending
N/A
Patents Pending
N/A
Patents Pending
280 (FY, 2016)
Patents Pending
115 (FY, 2016)
Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
4 (FY, 2016)
Phase I Trials Products
N/A
Phase I Trials Products
2 (FY, 2016)
Phase I Trials Products
1 (FY, 2016)
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
10 (FY, 2016)
Phase II Trials Products
N/A
Phase II Trials Products
4 (FY, 2016)
Phase II Trials Products
2 (FY, 2016)
Phase III Trials Products
Phase III Trials Products
N/A
Phase III Trials Products
2 (FY, 2016)
Phase III Trials Products
N/A
Phase III Trials Products
1 (FY, 2016)
Phase III Trials Products
2 (FY, 2016)

Funding

Total funding raised
Total funding raised
$ 21.3m
Total funding raised
N/A
Total funding raised
$ 9m
Total funding raised
$ 468.9m
Total funding raised
$ 153.4m
For sources of this data, please see the company profile

View company profiles

Biogen
HQ
Cambridge, US
Employees
7,800↑ 7% increase

Biogen is a biopharmaceutical company that discovers, develops and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases.

View company
Athersys
HQ
Cleveland, US
Employees
75↑ 14% increase

Athersys, a biopharmaceutical company, discovers and develops therapeutic products for the treatment of several disease indications.

View company
Reata Pharmaceuticals
HQ
Irving, US
Employees
123↑ 32% increase

Reata Pharmaceuticals is a biopharmaceutical company focused on translating innovative science into breakthrough medicines for intractable diseases.

View company
Otonomy
HQ
San Diego, US
Employees
49↓ 8% decrease

Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.

View company